Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer
暂无分享,去创建一个
S. Salerno | G. Scambia | A. Fagotti | V. Chiantera | G. Lo Re | G. Sozzi | Giulia Zaccaria | M. C. Di Donna | V. Giallombardo | G. Cucinella | A. Laganà | Agata Crapanzano
[1] P. Van Trappen,et al. Robotic surgery in early and advanced ovarian cancer: Case selection for surgical staging and interval debulking surgery. , 2022, European journal of obstetrics, gynecology, and reproductive biology.
[2] I. Zapardiel,et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) predictive score for complete resection in primary cytoreductive surgery , 2022, International Journal of Gynecological Cancer.
[3] E. Goode,et al. Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer. , 2022, Gynecologic oncology.
[4] J. Magrina,et al. Does MIS Play a Role in the Treatment of Advanced Ovarian Cancer? , 2022, Cancers.
[5] P. Cybulska,et al. Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer. , 2022, Gynecologic oncology.
[6] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[7] J. Berek,et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[8] S. Kehoe,et al. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. , 2021, The Cochrane database of systematic reviews.
[9] Kyunghwa Han,et al. CT-Based Fagotti Scoring System for Non-Invasive Prediction of Cytoreduction Surgery Outcome in Patients with Advanced Ovarian Cancer , 2021, Korean Journal of Radiology.
[10] K. Stålberg,et al. Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study , 2021, Cancer Imaging.
[11] J. Mountz,et al. Diagnostic Value of FDG PET/MRI in Females With Pelvic Malignancy—A Systematic Review of the Literature , 2020, Frontiers in Oncology.
[12] R. Raffaelli,et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? , 2020, Gland surgery.
[13] S. Rizzo,et al. Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. , 2019, European journal of radiology.
[14] D. Timmerman,et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] G. Scambia,et al. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy , 2019, International Journal of Gynecologic Cancer.
[16] B. Chiofalo,et al. Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis , 2019, Minerva medica.
[17] A. Sood,et al. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. , 2018, Gynecologic oncology.
[18] J. Escrig,et al. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index , 2018, World Journal of Surgical Oncology.
[19] G. Bogani,et al. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses , 2018, Journal of gynecologic oncology.
[20] G. Scambia,et al. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. , 2016, American journal of obstetrics and gynecology.
[21] G. Scambia,et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. , 2015, Gynecologic oncology.
[22] A. Sood,et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. , 2015, Gynecologic oncology.
[23] R. Granese,et al. Cytogenetic analysis of epithelial ovarian cancer's stem cells: an overview on new diagnostic and therapeutic perspectives. , 2015, European journal of gynaecological oncology.
[24] Douglas G Altman,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.
[25] H. Hricak,et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. , 2014, Gynecologic oncology.
[26] G. Scambia,et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. , 2013, Gynecologic oncology.
[27] R. Rouzier,et al. External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery. , 2011, Anticancer research.
[28] E. Sala,et al. ESUR guidelines: ovarian cancer staging and follow-up , 2010, European Radiology.
[29] G. Kenter,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.
[30] G. Scambia,et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? , 2010, Gynecologic oncology.
[31] G. Scambia,et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial , 2009, British Journal of Cancer.
[32] D. Jung,et al. Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer , 2009, European Radiology.
[33] R. Rouzier,et al. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. , 2008, Gynecologic oncology.
[34] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.
[35] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[36] D. Chi,et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. , 2007, Gynecologic oncology.
[37] B. Karlan,et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] G. Scambia,et al. A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study , 2006, Annals of Surgical Oncology.
[39] W. Cliby,et al. Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer , 2006, Obstetrics and gynecology.
[40] K. Brandt,et al. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma , 2004, Cancer.
[41] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] ESUR BOARD,et al. European Society of Urogenital Radiology (ESUR) , 2001, European Radiology.
[43] P. Sugarbaker,et al. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. , 1996, Cancer treatment and research.
[44] K. Jablonski,et al. Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.
[45] H. Hansen,et al. Performance status assessment in cancer patients. An inter-observer variability study. , 1993, British Journal of Cancer.
[46] C. Conill,et al. Performance status assessment in cancer patients , 1990, Cancer.